as of 12-09-2025 3:45pm EST
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 2.8B | IPO Year: | 2020 |
| Target Price: | $76.56 | AVG Volume (30 days): | 376.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $38.51 - $85.25 | Next Earning Date: | 11-04-2025 |
| Revenue: | $366,100,000 | Revenue Growth: | 182.44% |
| Revenue Growth (this year): | 147.24% | Revenue Growth (next year): | 53.11% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
President/CEO and Board Chair
Avg Cost/Share
$55.37
Shares
6,000
Total Value
$332,220.00
Owned After
812,106
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Sep 24, 2025 | Sell | $55.37 | 6,000 | $332,220.00 | 812,106 |
See how TARS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "TARS Tarsus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.